Effects of the novel long-acting GLP-1 agonist, albiglutide, on cardiac function, cardiac metabolism, and exercise capacity in patients with chronic heart failure and reduced ejection fraction
Understanding what the first four weeks of treatment actually looks like, based on available Phase 2 trial data, is essential for setting realistic expectations
The ability to monitor long-term health improvements through precise data, such as changes in BMI, fat percentage, and body composition, will allow insurance companies to provide better services while improving profitability
At best, people may waste money on an ineffective gimmick, and at worst, they may experience harmful drug interactions or adverse effects and compromise their health by delaying real evidence-based treatment
Its appeal extends beyond the peptides trend in the fitness and bodybuilding industries largely due to the mainstream popularity of GLP1 agonist weight loss drugs like Ozempic
The order in which you consume macronutrients also matters